Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2016 at the end of the period of market exclusivity.
On 13 March 2002, orphan designation (EU/3/02/092) was granted by the European Commission to Novartis Europharm Limited, United Kingdom, for 4-(3,5-bis-(hydroxy-phenyl)-1,2,4)triazol-1-yl)-benzoic acid for the treatment of chronic iron overload requiring chelation therapy.
4-(3,5-Bis(hydroxy-phenyl)-1,2,4) triazol-1-yl) benzoic acid
Treatment of chronic iron overload requiring chelation therapy
|Orphan designation status||
|EU designation number||
|Date of designation||
Novartis Europharm Limited
Documents related to this orphan designation evaluation
EU/3/02/092: Public summary of positive opinion for orphan designation of 4-(3,5-bis-(hydroxy-phenyl)-1,2,4) triazol-1-yl)-benzoic acid for the treatment of chronic iron overload requiring chelation therapy (PDF/119.29 KB)
First published: 28/02/2007
Last updated: 30/09/2016
EMEA/COMP/50/02 Rev. 4
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: